Importance of timing of radiotherapy in breast conserving treatment for early stage breast cancer

Radiother Oncol. 1994 Mar;30(3):206-12. doi: 10.1016/0167-8140(94)90459-6.

Abstract

This study reports on the treatment results in 508 patients with 514 AJCC stage I-II invasive breast carcinomas treated between July 1980 and July 1989. All patients underwent a lumpectomy with axillary lymph node dissection with postoperative irradiation. Adjuvant chemotherapy was given to premenopausal node-positive patients. Postmenopausal node-positive patients received adjuvant hormonal treatment. The median follow-up period was 68 months (range, 40-152 months). The 5-year survival rates were 92.6%, 81.4% and 65.5% for stage I, stage IIA and stage IIB, respectively. Distant metastases were the main cause of death. Locoregional failures occurred in 4.9%. Breast recurrences were detected in 17 patients (3.3%). In a Cox proportional hazards analysis, T-stage, pathological margins and interval between surgery and radiotherapy were identified as independent factors predictive of breast recurrence (p < 0.05). The results suggest that radiotherapy should be initiated early after surgery to maintain the breast recurrence rate as low as possible.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / pathology
  • Breast Neoplasms / radiotherapy*
  • Breast Neoplasms / surgery*
  • Carcinoma / radiotherapy
  • Carcinoma / secondary
  • Carcinoma / surgery
  • Carcinoma, Ductal, Breast / radiotherapy
  • Carcinoma, Ductal, Breast / secondary
  • Carcinoma, Ductal, Breast / surgery
  • Carcinoma, Lobular / radiotherapy
  • Carcinoma, Lobular / secondary
  • Carcinoma, Lobular / surgery
  • Chemotherapy, Adjuvant
  • Combined Modality Therapy
  • Female
  • Follow-Up Studies
  • Humans
  • Lymph Node Excision
  • Lymphatic Irradiation
  • Mastectomy, Segmental*
  • Middle Aged
  • Neoplasm Recurrence, Local / prevention & control
  • Neoplasm Staging
  • Radiotherapy Dosage
  • Radiotherapy, High-Energy*
  • Survival Rate
  • Time Factors